BioPharma Drug Discovery

European Commission Approves OBGEMSA™ (Vibegron) for Overactive Bladder Treatment by Pierre Fabre Laboratories

The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overac...

 July 01, 2024 | News

Cytiva Introduces Supor Prime Filters to Enhance High-Concentration Biologic Drug Manufacturing

Global life sciences leader Cytiva is addressing the distinct filtration needs of customers manufacturing high-concentration biologic drugs with its Supor ...

 June 28, 2024 | News

South Korea Approves Reimbursement for Antengene's XPOVIO®, Expanding Access to Relapsed/Refractory Multiple Myeloma Treatment

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treat...

 June 27, 2024 | News

Simcere Zaiming's Enlituo® Receives NMPA Approval for mCRC Treatment

Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetu...

 June 27, 2024 | News

EU Approves HUTCHMED's FRUZAQLA® for Previously Treated Metastatic Colorectal Cancer

— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZ...

 June 24, 2024 | News

Menarini Expands Partnership with Pharmacosmos to Bring Innovative Iron Deficiency Treatment to Singapore and Malaysia

Menarini Asia-Pacific (Menarini)  announced that it has expanded its partnership with Pharmacosmos A/S (Pharmacosmos), to include exclusive rights to ...

 June 19, 2024 | News

Ascentage Pharma Secures $1.3 Billion Deal with Takeda for Global Rights to Olverembatinib

Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas. ...

 June 17, 2024 | News

SciRhom GmbH Secures Approval for Clinical Trial Application of SR-878 in Austria

SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced the approval of a clinical trial a...

 June 14, 2024 | News

Ochre Bio and GSK Enter Multi-Year Partnership to Advance Liver Disease Research

Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The part...

 June 13, 2024 | News

Gilead and Kite Oncology Announce Approval of Yescarta® for Early Treatment of DLBCL in Singapore

    **-- In ZUMA-7, Yescarta Patients with DLBCL were 2.5 Times More Likely than SOC to be Alive at Two Years Without Cancer Progression or Nee...

 June 10, 2024 | News

Luye Pharma and Towa Pharmaceutical File NDA in Japan for Rivastigmine Twice Weekly Patch for Alzheimer’s

Luye Pharma Group announced that its partner Towa Pharmaceutical Co., Ltd. (Towa) has filed a New Drug Application (NDA) to the Ministry of Health, Labour ...

 June 07, 2024 | News

Eisai Co., Ltd. Expands Venture Investment to Accelerate Drug Discovery Innovation

Eisai Co., Ltd. announced that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of disc...

 June 04, 2024 | News

Eisai Co., Ltd. Expands Venture Investment to Accelerate Drug Discovery Innovation

Eisai Co., Ltd. announced that the company decided to strengthen and continue its venture investment business, which launched in 2019, with the aim of disc...

 June 04, 2024 | News

Telix Pharmaceuticals Completes BLA Submission to FDA for Breakthrough Kidney Cancer Imaging Agent TLX250-CDx

Telix Pharmaceuticals announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food an...

 June 03, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close